CITATION: MediPharm v. Hexo and Hwang, 2022 ONSC 4326  
COURT FILE NO.: CV-20-212  
DATE: 20220725  
MediPharm Labs Inc., Plaintiff (Defendant to the Counterclaim), Moving Party  
Hexo Operations Inc., Defendant (Plaintiff by Counterclaim), Responding Party  
Peter Hwang, Defendant by Counterclaim, Moving Party  
Justice Spencer Nicholson  
COUNSEL: M. Polvere and J. Leslie for the Plaintiff, MediPharm Labs Inc.  
J. Teskey and A. Visvanatha for the Defendant, Hexo Operations Inc.  
E. Lederman and S. Hale for the Defendant by Counterclaim, Peter Hwang  
December 8, 2021  
In October of 2018, Canada became the first of the G7 countries to legalize cannabis  
sales, sparking a quickly evolving, mega-million dollar industry.  
MediPharm Labs Inc. (“MediPharm”) produces purified pharmaceutical grade cannabis  
oil and cannabis concentrates to be used in cannabis derivative products.  
Hexo Operations Inc. (“Hexo”) produces, markets and sells branded cannabis products to  
provincial boards and commercial retailers.  
UP Cannabis Inc. (“UP Cannabis”) was licensed to cultivate, process and sell cannabis  
for the recreational market. Newstrike Brands Ltd. (“Newstrike”) was the parent  
company of UP Cannabis. Peter Hwang was a director of Newstrike.  
This case involves a Supply Agreement pursuant to which MediPharm was to supply  
cannabis resin to UP Cannabis from March 2019 to February 2020. The Supply  
Agreement is dated February 11, 2019. At the time, it was the biggest supply agreement  
involving cannabis products.  
Hexo purchased Newstrike pursuant to an Arrangement Agreement dated March 12, 2019  
with a closing date of May 24, 2019. Hexo therefore acquired UP Cannabis and became  
responsible for its contractual obligations pursuant to the Supply Agreement.  
MediPharm has commenced an action against Hexo for unpaid invoices for the cannabis  
resin that it supplied to Hexo pursuant to the Supply Agreement. MediPharm alleges that  
the unpaid amount is $9,802,032.78.  
Hexo has counterclaimed against MediPharm and Mr. Hwang for $35,000,000.00. The  
counterclaim against MediPharm is grounded in breach of contract, breach of its  
obligation of good faith dealing and unjust enrichment. The counterclaim against Mr.  
Hwang is based on breach of fiduciary duty and/or breach of his obligation of good faith  
Both MediPharm and Mr. Hwang bring motions for summary judgment. MediPharm  
asserts that there is no genuine issue requiring a trial with respect to whether Hexo owes  
MediPharm for the product Hexo requested and MediPharm supplied. Mr. Hwang asserts  
that there is no genuine issue for trial with respect to the counterclaim against him  
because he is protected by the business judgment rule which calls for deference to  
business decisions so long as they fall within a range of reasonable alternatives.  
[10] Hexo opposes the motions asserting that the issues in the claim and counterclaim require  
a trial to resolve.  
[11] The issues are whether there is a genuine issue requiring a trial with respect to the unpaid  
invoices or the counterclaims.  
Evidence on the Motions:  
Newstrike’s Strategic Business Plan:  
[12] Mr. Hwang was a director of Newstrike. In July of 2018, he was appointed Chief  
Commercial Officer and in January of 2019, he was appointed President, Operations. He  
was responsible for leading all commercial activities in Sales, Marketing and Operations  
and was in charge of leading Newstrike’s New Product Development department. As  
part of its operations, Newstrike entered into various partnerships and agreements in  
furtherance of its strategic business plan.  
[13] It is important to understand that the legalization of cannabis derivative products, for  
example, vapes, edible, beverages, etc., was expected to occur in late 2019. These  
derivative products were known as “Cannabis 2.0 products”. According to the evidence  
of Mr. Hwang, Newstrike was focused from at least March of 2018 on preparing for this  
legalization of Cannabis 2.0 products. It was anticipated that cannabis derivative  
products, when legalized, would generate higher margins and greatly expand the target  
demographic of the cannabis industry. As part of that preparation, Newstrike in late 2018  
and early 2019 was:  
(a) Acquiring the cannabis oil necessary for the production of these Cannabis 2.0  
(b) Developing internal cannabis oil extraction capabilities and expertise to sustain  
long-term production of Cannabis 2.0 products;  
(c) Stockpiling and building an inventory of cannabis oil to satisfy production  
(d) Entering into partnerships with food, beverage and other service providers for the  
creation of several lines of Cannabis 2.0 products;  
(e) Securing shelf-space for Cannabis 2.0 products in retail shops across Canada; and  
(f) Producing and selling excess cannabis oil to other licenced producers or directly  
to consumers.  
[14] I pause to note that in his affidavit, Mr. Hwang uses the term “oil” to describe the product  
Newstrike was seeking to further its strategic business plan. Mr. McMillan, Chief  
Development Officer for Hexo, describes in his affidavit that there is a significant  
difference between “oil” and “resin”. According to Mr. McMillan, resin could not be  
used without being further processed. He asserts that UP Cannabis did not have the  
appropriate facilities to do so. Furthermore, UP Cannabis did not have the proper licence  
to sell cannabis oil. Moreover, Mr. McMillan asserts that resin has a short shelf-life,  
making it impractical to store in large quantities. On his cross-examination, Mr. Hwang  
indicated that he understood the difference between resin and oil but would use the word  
“oil” loosely in some contexts.  
[15] Both Mr. McMillan and Mr. Shehata for MediPharm discuss winterized resin in their  
affidavits in similar fashion. Mr. Shehata, in MediPharm’s Reply Affidavit, describes  
that it supplied winterized cannabis resin pursuant to the Supply Agreement. Mr. Shehata  
states that cannabis resin can be comprised of either CBD or THC cannabinoid  
components. Further, he describes that winterization is a refinement process used to  
remove fats, waxes and lipids from extracts. The winterization of oil purifies crude  
extracts, increasing the quality and flavour of the resultant oil. In the process, cannabis  
extract is mixed with ethanol and frozen to allow the undesirable compounds to solidify.  
The solution is then passed through a filter, separating wax, lipids and fats from the oil.  
In the final step, the ethanol is removed, resulting in a winterized extract. If the extract is  
then “stripped” of all materials and compounds except one specific cannabinoid, it results  
in distillate. It is the distillate that is the base ingredient of most edibles and vapes and is  
a potent cannabis oil. The most common forms of distillate on the market are THC oil  
and CBD oil or a combination of the two.  
[16] Mr. Hwang’s affidavit includes significant detail in respect of Newstrike’s efforts in 2018  
to further its plans. In September and December of 2018, Newstrike, through UP  
Cannabis, entered into two agreements with MediPharm. Pursuant to those agreements,  
Newstrike sold specific quantities of cannabis flower and shake to MediPharm.  
MediPharm, in turn, would extract cannabis oil from the flower and shake. Newstrike  
retained a right of first refusal over the extracted cannabis oil.  
[17] In the meantime, Newstrike had made it known that it was interested in being acquired.  
Hexo was identified as a potential purchaser. Mr. McMillan deposes that it was well  
known in the fall of 2018 that Newstrike was seeking out a buyer. In any event, the two  
companies became involved in “talks” in relation to the potential acquisition in late 2018  
or early 2019. Mr. Hwang points out that in 2018 Newstrike had been in talks with other  
potential buyers and that those deals had all fallen through.  
[18] Mr. Hwang deposes that Newstrike had to ensure its preparedness for the legalization of  
Cannabis 2.0 products. Thus, it could not afford to put its plans on hold. Had plans for  
the acquisition by Hexo not come to fruition, Mr. Hwang deposes that a failure to  
implement its strategic business plan would have been fatal to the viability of Newstrike.  
Thus, in early 2019, Newstrike, through Travis Kanellos, its Director of Business  
Development, was discussing with MediPharm the possibility of a further agreement.  
MediPharm’s representative for these discussions was Pat McCutcheon, its Chief  
Executive Officer.  
[19] In January of 2019, Newstrike hired Trevor Folk as its Vice President, New Products.  
Mr. Folk is described as an experienced extraction expert and he was to lead the  
company’s new product development and develop its internal extraction capabilities. It  
was hoped that Mr. Folk’s relationships with other licensed producers would result in  
Newstrike being able to stockpile a large enough oil inventory to sell to other licensed  
producers at a premium. During his cross-examination, Mr. Hwang makes it clear that  
Trevor Folk was to play a major role in developing the extraction capabilities from which  
oil distillates could be obtained from the resin obtained from MediPharm.  
[20] Mr. Hwang describes that ultimately Newstrike planned to expand its facility in early  
2019 to house additional extraction and production facilities. They would also obtain the  
necessary licences. These plans were put on hold when the potential acquisition by Hexo  
was being negotiated.  
[21] I return to the distinction between oil and resin. Mr. Hwang deposes in his affidavit as  
follows (at para. 42):  
“42. As mentioned in the Strategic Business Plan above, the production of  
cannabis derivative products requires cannabis oil and resin, which is extracted  
from cannabis plants. Until Newstrike hired Trevor Folk, it did not have its own  
internal extraction capability. However, Newstrike recognized that early access to  
large quantities of cannabis oil would ensure a head-start in terms of creating,  
developing and ensuring Newstrike’s Cannabis 2.0 products were ready for  
market immediately upon legalization. As such, and while it worked on building  
its own in-house oil production, Newstrike sought to procure cannabis oil from  
external sources.”  
[22] On January 31, 2019, MediPharm sent Mr. Kanellos a Letter of Intent with respect to  
initiating a wholesale cannabis resin supply agreement. Ultimately, the parties agreed to  
the Supply Agreement dated February 11, 2019 between UP Cannabis and MediPharm.  
The Supply Agreement was negotiated and drafted by legal counsel representing both  
parties. Mr. Hwang testified that in addition to himself, Mr. Kanellos, Mr. Folk and  
Newstrike’s legal counsel were instrumental in the negotiation on behalf of UP Cannabis.  
The legal counsel included Ms. Ruth Chun, who the evidence establishes was  
experienced in large transactions involving cannabis sales.  
[23] The negotiations leading to the Supply Agreement were the subject of considerable  
exploration by Hexo during the cross-examinations of Mr. Shehata, affiant for  
MediPharm and then of Mr. Hwang. They both made it clear that 12 days was not an  
unusually short time for negotiations to occur, even given the magnitude of the deal.  
They each indicated that due to their previous arrangements, there was some familiarity  
with each other. MediPharm had done similar deals in the past with other parties. I find  
as a fact that there was nothing improper about the negotiations taking only 12 days to  
[24] I will address the key terms of the Supply Agreement in greater detail below. Generally,  
the Supply Agreement required MediPharm to supply cannabis resin concentrate to UP  
Cannabis over a 12-month period. It also obligated UP Cannabis to purchase a certain  
amount of resin. There was to be an initial delivery of 142.7 kg of cannabis resin.  
Thereafter, MediPharm would deliver 50 kg of resin every month. UP Cannabis had an  
option to purchase an additional 25 kg of resin per month. In dollar figures, this was  
approximately $35 million worth of cannabis resin concentrate over a period of 12  
months, with the option to purchase an additional $13.5 million worth. All told, there  
would be 13 mandatory shipments of resin for the months of February 2019 through  
February 2020.  
[25] According to Mr. Hwang, the Supply Agreement was beneficial to Newstrike as, inter  
alia, it would provide a reliable and predictable supply of the cannabis oil (the word he  
uses) necessary to achieve its plans in relation to Cannabis 2.0 products. He deposes that  
the prices set out in the Supply Agreement were fair and in line with market prices at the  
time. The price per mg of active component was $0.07 in February of 2019 for the first  
142.7 kg and thereafter $0.06 per mg.  
[26] MediPharm produced other supply agreements entered into in 2018 and 2019 as  
undertakings on Mr. Shehata’s cross-examination. I have reviewed carefully the prices  
contained therein. I note that the majority of these contracts are for the sale of cannabis  
resin, although at least one is for cannabis oil. I had initially included the specifics of the  
pricing within my decision. However, I have rewritten this paragraph to omit specific  
pricing so as not to jeopardize what could be considered confidential information.  
Suffice it to say that the pricing in the contracts produced by MediPharm as part of their  
undertakings demonstrate that the price agreed to in the Supply Agreement was  
consistent with the prices negotiated between MediPharm and other parties. These  
agreements certainly refute the allegation that the Supply Agreement contains inflated  
prices for cannabis resin.  
[27] Furthermore, Mr. Hwang describes that MediPharm’s expertise was specifically  
important to Newstrike. Unlike other licensed producers, MediPharm was a cannabis  
extractor specializing in producing cannabis oil and cannabis concentrates for derivative  
products. That expertise, in short, was worth paying an increased price.  
[28] In its material, MediPharm points out that the initial Letter of Intent included prices that  
were 33% higher. The prices ultimately agreed to by MediPharm and UP Cannabis were  
negotiated down from MediPharm’s initial offer.  
[29] Mr. Hwang’s affidavit details several areas with respect to Cannabis 2.0 products that  
Newstrike was exploring. This included edibles, vape products, beverages and personal  
care products. He has included projected revenue from these areas and the entities that  
Newstrike was attempting to form partnerships with to develop the products. This is  
corroborated by correspondence. Mr. Hwang explains that these endeavours all required  
large quantities of cannabis oil.  
[30] Mr. Hwang describes that bulk cannabis oil was difficult to obtain in the months leading  
up to the legalization of Cannabis 2.0 products. He states that only a limited number of  
licensed producers were producing cannabis oil and very few bulk purchase opportunities  
existed. He emphasizes that any oil that was not used for production or sold, could be  
stockpiled for future use or sale.  
Specific Terms of the Supply Agreement:  
[31] Both Hexo and MediPharm sought to characterize the Supply Agreement. It is helpful to  
turn to its important provisions.  
[32] The Supply Agreement contained a number of “defined terms”. For example,  
“Active Component” meant THC or CBD;  
“Goods” meant the Cannabis Resin to be supplied hereunder by the Supplier to  
the Purchaser, including the Goods as described in Schedule A;  
[33] All parties were in agreement that the Supply Agreement did not specify which of THC  
or CBD resin MediPharm was required to provide. In his affidavit, Mr. McMillan  
specifically complains that the Supply Agreement did not provide UP Cannabis with such  
a protection.  
[34] Pursuant to Schedule B to the Supply Agreement, UP Cannabis agreed to purchase, and  
MediPharm agreed to sell the “total quantities of bulk winterized Cannabis Resin set out  
in the table below”. Accordingly, there was a minimum quantity of resin that the parties  
agreed would be sold from MediPharm to UP Cannabis. Under Schedule B, there was  
also a late penalty in the event that MediPharm provided the goods ordered late.  
[35] The Supply Agreement provided that the UP Cannabis shall issue Purchase Orders to  
MediPharm via email. MediPharm was then to confirm via email receipt of the Purchase  
Order. MediPharm could then confirm acceptance or rejection of the Purchase Order. If  
MediPharm did not confirm its acceptance or rejection, it was deemed to have accepted  
the Purchase Order. The Supply Agreement was silent on what would happen if UP  
Cannabis did not issue a Purchase Order. However, as noted above regarding Schedule  
B, UP Cannabis had obligated itself to purchase resin on a monthly basis throughout the  
term of the Supply Agreement. Thus, I agree with MediPharm that it was not open to  
Hexo or UP Cannabis to choose not to send Purchase Orders.  
[36] Under the Supply Agreement, MediPharm warranted, inter alia, that the Goods would  
comply with all Applicable Law, be free of any and all pesticides and be free of  
unwanted contaminants. There was a procedure for lab testing set out in the Supply  
[37] UP Cannabis agreed that it would pay 50% of the initial Purchase Order it received from  
MediPharm within five business days of the execution date of the Supply Agreement and  
the remaining 50% within five business days of the delivery of the Goods. For the  
balance of the purchases, provided that an invoice was delivered by MediPharm, UP  
Cannabis would pay 50% on the first business day of each month and the remaining 50%  
of the amount within five business days of the delivery of the Goods.  
[38] UP Cannabis could terminate the Supply Agreement upon ten business days prior written  
notice if MediPharm was in breach of any material representation, warranty, covenant or  
obligations in any material respect that causes or is reasonably expected to cause material  
financial harm to UP Cannabis. However, MediPharm had 30 days in which to cure such  
breach or default.  
[39] Importantly, the Supply Agreement contained an Entire Agreement clause (clause 13.3)  
and a clause providing that no amendment or waiver of any provision of this Agreement  
would be binding on either party unless consented to in writing by that party (clause  
The Acquisition:  
[40] As noted, talks in relation to the acquisition by Hexo of Newstrike began in the fall of  
2018. There was a non-disclosure agreement between Hexo and Newstrike signed on  
November 30, 2018. Prior to February 11, 2019, Newstrike provided Hexo with a  
Confidential Information Memorandum. The Confidential Information Memorandum  
provided an overview of Newstrike’s operations and its strategic business plan. The  
memorandum included reference to Newstrike’s need for cannabis oil as it planned for  
the legalization of Cannabis 2.0 products.  
[41] Additionally, management from Hexo, Newstrike and UP Cannabis held in person  
meetings to discuss the acquisition, Hexo toured Newstrike facilities and Newstrike’s  
Board of Directors had formed a special committee in relation to the potential acquisition.  
[42] Importantly, Hexo was afforded an opportunity to conduct due diligence with respect to  
the Newstrike acquisition. The due diligence process commenced on March 13, 2019  
and lasted until May 24, 2019, the date for closing. Mr. McMillan testified that Hexo had  
over 20 individuals involved in the overall due diligence concerning the acquisition.  
[43] In early 2019, Newstrike and Hexo executives met multiple times, in person and by  
telephone. On February 25, 2019, Hexo provided Mr. Hwang with a due diligence  
request list, which included a request for all material agreements. According to Mr.  
Hwang, all material agreements, including the Supply Agreement, were placed into a data  
room for Hexo’s review. This was acknowledged by Mr. McMillan during cross-  
[44] Of note, Mr. Hwang was not on the Newstrike investment committee that was interacting  
with the Hexo team for the purpose of the acquisition.  
[45] Both Newstrike and Hexo were represented by legal counsel and business advisors  
throughout the negotiations for the acquisition. On March 12, 2019, the parties executed  
the Arrangement Agreement. Hexo was to acquire Newstrike’s shares in an all-share  
transaction valued at approximately $263 million. Effectively, Hexo purchased  
Newstrike and its subsidiaries, which included UP Cannabis. Hexo would become  
responsible for all contracts to which Newstrike, or its subsidiaries, were a party. This  
included the Supply Agreement. The closing date for the acquisition was May 24, 2019.  
[46] At the time that the Arrangement Agreement was entered into the parties also executed a  
Disclosure Letter, stated to be “read and understood as an integrated document”. The  
Disclosure Letter, among other things, set out the material contracts to which Newstrike  
was a party at the time of the Arrangement Agreement. This included the various  
agreements with MediPharm, including the Supply Agreement.  
[47] The Arrangement Agreement contained several relevant provisions. Section 3 of the  
Arrangement Agreement addressed representations and warranties. Except for certain  
representations and warranties as set out in the contemporaneously delivered Disclosure  
Letter, Schedule D contained representations and warranties upon which Hexo could rely.  
However, the representations and warranties were expressly not to survive the  
consummation of the Arrangement and expired on the date of closing. Clause 9.7 is an  
“Entire Agreement Clause” indicating that only the Arrangement Agreement, the  
Disclosure Letter and the Confidentiality Agreement made up the entire agreement.  
Section 9.12 provided as follows:  
9.12 No Liability  
No director or officer of Purchaser shall have any personal liability whatsoever to  
Company or any third-party beneficiary under this Agreement and the Plan of  
Arrangement or any other document delivered in connection with the  
Contemplated Transactions on behalf of Purchaser. No director or officer of  
Company shall have any personal liability whatsoever to Purchaser under this  
Agreement and the Plan of Arrangement or any other document delivered in  
connection with the transactions contemplated hereby on behalf of Company.”  
[48] Newstrike and Hexo issued a public announcement on March 13, 2019 advising of  
Hexo’s intention to acquire Newstrike.  
[49] According to Mr. Hwang, the Supply Agreement was specifically discussed on April 9,  
2019. Two representatives of Hexo spoke with Newstrike’s Chief Financial Officer who  
explained the rationale for the Supply Agreement. The Chief Financial Officer prepared  
a memo of that meeting in which he indicates that he advised that they were having  
“speed bumps” in relation to having to accept THC instead of CBD as well as a few lots  
of the February shipment presenting with a “quality issue”. Importantly, on his cross-  
examination, Mr. McMillan admitted that he did not speak to either of the two Hexo  
representatives to determine whether or not this conversation took place, or, if so, the  
substance of it. Accordingly, this evidence is unrefuted.  
[50] On May 15, 2019, Mr. McMillan, followed up with Mr. Kanellos with respect to the  
Supply Agreement, via email. Mr. McMillan asked for updates on the status of the  
deliveries from MediPharm and on Newstrike’s efforts to sell its inventory of cannabis  
[51] On May 17, 2019, Mr. Hwang deposes that Stephen Burwash, the interim Chief Financial  
Officer of Hexo, wrote to him and asked to meet to discuss the Supply Agreement.  
During a conference call on May 21, 2019, the pricing logic and overall reasoning behind  
the Supply Agreement were discussed. According to Mr. Hwang, at no time during that  
discussion did Hexo raise any concern about the pricing, volumes or business efficacy of  
the Supply Agreement.  
[52] Hexo takes the position that no such detailed discussion regarding the Supply Agreement  
occurred at this meeting. Mr. McMillan, on cross-examination, could not recall for sure  
whether or not he had participated in that meeting. He relies upon Mr. Burwash advising  
him that no such discussion occurred.  
[53] Hexo’s acquisition of Newstrike closed as scheduled on May 24, 2019. Thereafter, Hexo  
assumed all rights and obligations under any supply agreements, including the Supply  
Agreement with MediPharm. Mr. Hwang argues that by that time, Hexo had been fully  
apprised of the details of Newstrike’s relationship with MediPharm, Newstrike’s  
inventory of cannabis resin and had been informed of the rationale for the Supply  
Agreement from a business perspective.  
[54] On May 31, 2019, Mr. Hwang was terminated from his positions at Newstrike and UP  
Cannabis effective June 30, 2019. Upon the completion of the Arrangement Agreement,  
the members of the boards of Newstrike and its subsidiaries were required to resign. Mr.  
Hwang deposes that he has had no further involvement in the business of either company  
since that time. Furthermore, Trevor Folk and Mr. Kanellos were also terminated  
immediately after the merger. This is an important fact given that it was Mr. Folk’s  
expertise that UP Cannabis had intended to rely upon to extract the oil from the resin  
acquired from MediPharm and his involvement was instrumental to the strategic business  
[55] I should also note that Newstrike was Hexo’s first acquisition.  
Performance of the Supply Agreement:  
[56] MediPharm began supplying cannabis resin to UP Cannabis pursuant to the Supply  
Agreement, with the first shipment being made on or about February 22, 2019. That  
shipment was for 47 kg and was paid for by UP Cannabis. A further 95.7 kg shipment  
was made on March 1, 2019 and subsequently paid for. The shipments for February,  
March and April of 2019 were all made prior to Hexo acquiring Newstrike.  
[57] Almost immediately, there is evidence that UP Cannabis sought to review the Supply  
Agreement. Mr. Kanellos emailed Mr. McCutcheon of MediPharm on March 5, 2019  
and stated, “If you guys are up for it lets potentially look to lessen terms after we build up  
over the next few months…?”. Internal emails from UP Cannabis show that as early as  
March 11, 2019, they were seeking out buyers for the resin that they had just acquired  
from MediPharm and prepared to sell at a loss. On March 14, 2019, Mr. Hwang wrote  
that one possible option was “…Discuss with Hexo the option for them to take the  
product if they want it but also more importantly also discuss the MediPharm agreement  
with them and see if long term it makes sense…”.  
[58] There are also a series of text messages between Mr. Hwang and Pat McCutcheon of  
MediPharm from March of 2019. The two are clearly discussing a dispute about the  
Supply Agreement and what has been agreed upon. It is apparent that performance of the  
Supply Agreement had already gotten off to a rocky start. However, nothing about the  
texts suggests that there was any collusion between Mr. Hwang and MediPharm. If  
anything, MediPharm is suggesting UP Cannabis is in breach for non-payment. Of note,  
Mr. McCutcheon does reference that MediPharm had initial concerns at the time that the  
Supply Agreement was being negotiated that UP Cannabis did not have the ability to  
“manage such a process or such robust volumes”.  
[59] Hexo complains that the February 2019 shipment was not tested for pesticides. In March  
of 2019, prior to Hexo’s acquisition, emails between MediPharm and UP Cannabis refer  
to two issues. The first is that there was a higher content of the pesticide Remesthrin than  
is permitted by Health Canada and secondly, that there was a “N/A” marking for the  
pesticide Kinoprene. It became apparent that MediPharm was not testing cannabis  
concentrates for all pesticides. Pesticide testing was the subject of a telephone  
conference between the parties. It was resolved that MediPharm would arrange to have  
the shipments tested for pesticides.  
[60] Reference is made to a positive test for the February 2019 shipment for the pesticide  
Acequinocyl. It appears that this shipment was quarantined. However, as pointed out by  
MediPharm, this was apparently a false positive. Hexo acknowledges this in their  
affidavit and has included a copy of the report dated June 12, 2019 confirming that fact. I  
find that the pesticide issue is a non-issue in this case.  
[61] Hexo also raises an alleged issue with the cannabis potency of the initial shipments being  
below the potency indicated in the original MediPharm invoice. Ultimately, MediPharm  
gave UP Cannabis a credit in the amount of approximately $150,000 as a result of the  
deficiency. UP Cannabis accepted the credit and the shipment.  
[62] Upon UP Cannabis’ concerns being addressed to UP Cannabis’ satisfaction, the evidence  
is clear that these invoices were ultimately paid in full. The evidence establishes that  
MediPharm attempted to work with UP Cannabis to resolve these issues to their mutual  
satisfaction. In an email dated March 13, 2019, UP Cannabis had stated that they would  
not pay invoices in relation to those shipments until the product was approved as  
acceptable. MediPharm points out that they have now done so.  
[63] Mr. McMillan deposes that in June of 2019, he met with MediPharm personnel to discuss  
“traceability”. In Hexo’s view, from a regulatory standpoint, it was important to be able  
to show a link between the resin and the plant from which it came. Furthermore, at  
around the same time, Mr. McMillan met with MediPharm’s president, Keith Strachan, to  
discuss a possible addendum to the Supply Agreement that would require MediPharm to  
supply Hexo with cannabis concentrate in distillate form. Mr. McMillan specifically uses  
the phrase “indicated an interest in supplying other products, such as distillate, …at no  
extra cost to Hexo”. Mr. McMillan deposes that it was agreed that MediPharm would  
provide Hexo with a proposal for distillate and that MediPharm would be able to provide  
the additional processing at no additional cost. He states that MediPharm agreed to  
consider taking back the resin that had been supplied to Hexo, to distill it. I emphasize  
that the operative word used by Mr. McMillan is “consider”. According to Mr.  
McMillan, ongoing discussions occurred in July 2019 with a view to renegotiating the  
Supply Agreement.  
[64] Notwithstanding these discussions, MediPharm sent delivered product for the months of  
May and June 2019. Hexo complains that the shipments for May and June 2019 were  
made by MediPharm without having received the requisite Purchase Orders from UP  
Cannabis. Hexo states that MediPharm had no way of knowing what product Hexo  
[65] The July 2019 discussions are confirmed by an email from Mr. Shehata to Mr. McMillan  
dated July 17, 2019. Therein, Mr. Shehata noted that he would be happy to work with  
Hexo’s legal team to amend the Supply Agreement to reflect a new arrangement whereby  
MediPharm would supply distillate instead of resin, with additional fees being charged by  
MediPharm. He also indicated that MediPharm would be willing to accept the return of  
the May and June 2019 shipments so that MediPharm could process the resin into  
distillate at a nominal fee. Importantly, there is no correspondence by return from Hexo  
indicating that the parties had already agreed to MediPharm providing distillate at no  
extra cost. I note that pursuant to the terms of the Supply Agreement, any amendment  
was to be done in writing.  
[66] Hexo found MediPharm’s proposal with respect to extra costs for add-on services to be  
exorbitant. Mr. McMillan deposes that these costs would result in no profit margin for  
Hexo. Despite further discussions with Mr. Shehata, Hexo did not agree to pay the  
additional fees for the supply of cannabis concentrate in distillate form and the Supply  
Agreement was not amended.  
[67] On August 8, 2019, legal counsel for MediPharm wrote to Hexo seeking payment of  
$8,138,814.51 purportedly owing under the Supply Agreement.  
[68] On August 19, 2019, a new person at Hexo, Mr. Korec, assumed responsibility for the  
account. Mr. Korec advised MediPharm not to ship any product without a Purchase  
Order from Hexo and that Hexo wanted only the CSCJ CBD strain of product.  
[69] Significantly, Hexo decided to pay the outstanding amounts. Mr. McMillan described  
this as being in the hopes that Hexo and MediPharm would eventually agree to amend the  
arrangement so that MediPharm would supply distillate. Thus, the May and June 2019  
shipments were paid for on August 21, 2019.  
[70] On September 10, 2019, counsel for Hexo wrote to counsel for MediPharm indicating  
that it was Hexo’s position that MediPharm was in breach of the Supply Agreement by:  
(a) delivering products/goods not tested for pesticides;  
(b) overcharging Hexo for products containing a lower CBD potency than as  
expressly contracted for;  
(c) failing to supply goods of the character or quality contracted for;  
(d) shipping products without Purchase Orders being issued by Hexo;  
(e) insisting upon deposits which were not contemplated by the Supply Agreement.  
[71] On September 20, 2019, Mr. Korec attended the MediPharm facility and advised  
MediPharm that Hexo did not require any further THC product. According to Mr.  
McMillan, MediPharm agreed that it would deliver CBD products for July and August  
2019. Therefore, Mr. Korec sent Purchase Orders for 50 kg of CSCJ strain of CBD  
product for the July, August, September and October 2019 shipments. Despite this  
apparent agreement, on the same day, MediPharm advised that based on timing, it was  
not an option for MediPharm to ship CBD for the July and August 2019 shipments.  
MediPharm indicated that the Supply Agreement did not guarantee the resin type that  
would be shipped.  
[72] Without receiving confirmation from Hexo to proceed, MediPharm shipped the July,  
August and September 2019 shipments on September 30, 2019. The July and August  
2019 shipments consisted of THC resin, contrary to the Purchase Orders which  
specifically requested 50 kg of the high CBD potency CSCJ strain.  
[73] In his affidavit, Mr. Shehata explains that while he agrees that Mr. Korec attended their  
facilities in September 2019 and requested CBD product going forward, they advised him  
that they had already produced THC in good faith for the July and August 2019  
shipments based on their earlier shipments. He indicates that MediPharm was afraid to  
receive a late penalty for failing to ship product, so they shipped THC. He further  
deposes that they would accommodate the request for CBD provided that Hexo delivered  
Purchase Orders in advance so that they could prepare the requested product.  
[74] On October 8, 2019, Hexo rejected the 100 kg of THC resin for the July and August 2019  
shipments on the basis that Hexo did not require that inventory and the shipment did not  
fulfill Hexo’s issued Purchase Orders. Hexo refused to pay the remaining balances for  
the July and August 2019 shipments until MediPharm shipped the product that Hexo  
required and for which Hexo had issued Purchase Orders.  
[75] Thus, while the deposits were paid for the July and August 2019 shipments, the balance  
of $2,500,227.85 remained unpaid.  
[76] MediPharm did, in fact, agree to exchange the THC product for CBD product and  
actually exchanged the product. That exchange occurred in late November or December  
of 2019. Notwithstanding the exchange, Hexo has continued to refuse to pay the  
outstanding balance for the July and August 2019 shipment.  
[77] Hexo paid the September 2019 shipment in full. The September 2019 shipment was for a  
CBD strain. The Purchase Order from Hexo for that shipment was received by  
MediPharm on September 23, 2019.  
[78] MediPharm delivered the October 2019 shipment, which was 50 kg of a CBD strain as  
requested by a Hexo Purchase Order. Hexo paid the deposit, but not the balance in  
relation to that shipment. Thus, a further $1,287,647.66 went unpaid.  
[79] Hexo sent a Purchase Order in relation to the November 2019 shipment on October 31,  
2019. Again, this was for a strain of CBD resin. This was followed by an email from  
Hexo to MediPharm dated November 14, 2019 asking for a quote in the event that Hexo  
wanted to purchase distillate instead of winterized resin for the remainder of the Supply  
Agreement. I note that this email is inconsistent with MediPharm’s representatives  
already having promised to do so at no extra charge. According to Mr. McMillan’s  
affidavit, the MediPharm representative indicated that he would look into it and asked if  
Hexo wanted CBD or THC. The response was CBD. Hexo followed up this request with  
a further email dated November 21, 2019. In response to these emails, MediPharm never  
sent a quote for distillate.  
[80] On November 29, 2019, Hexo sent a further Purchase Order for the December shipment  
for 50 kg of CBD.  
[81] In addition to the exchanged resin, Hexo received the product delivered for the October,  
November and December 2019 shipments all between November 21 and December 30,  
2019. Thus, Hexo complains that it received 250 kg of resin in a 39-day period. From  
the record before me, there is no dispute that Hexo did receive the cannabis it requested  
(CBD) by Purchase Order.  
[82] Hexo did not pay the deposit for the January 2020 shipment. Given the state of the  
arrears, MediPharm did not deliver any product for January 2020. Instead, on January  
24, 2020, MediPharm issued a Statement of Claim seeking payment of $9,802,032.78, the  
amount alleged went unpaid by Hexo, including the January 2020 deposit.  
[83] On February 20, 2020, Hexo wrote to MediPharm seeking confirmation that MediPharm  
would accept the return of over 250 kg of THC resin supplied to Hexo, claiming it was  
supplied in breach of the Supply Agreement. MediPharm has not agreed to accept the  
return of the THC resin. Hexo did not offer to return the CBD resin. Mr. Shehata on  
cross-examination indicated it would be “stupid” for MediPharm to accept the return of  
the THC since the THC had been fully paid for by UP Cannabis/Hexo and since it had  
been out of MediPharm’s possession for so long, MediPharm could not be assured of its  
[84] Mr. McMillan describes that Hexo had to make the “best of a very difficult situation”. In  
order to avoid storing the resin for so long that it started losing its potency, Hexo  
attempted to use as much of the resin in its inventory as possible. It had to be processed  
and Hexo engaged a third party to process some of the resin into distillate. This was done  
at additional costs to Hexo. Accordingly, Hexo complains that it is losing money on  
products containing distillate derived from the resin received from MediPharm.  
[85] There is evidence that a third party, Teal Valley, offered to purchase some of the  
cannabis resin from UP Cannabis prior to the closing date of the acquisition. This was  
mentioned to Hexo on May 30, 2019. However, Hexo did not enter into this opportunity.  
Hexo says that Teal Valley was not interested in purchasing resin, but only oil.  
Positions of the Parties:  
[86] MediPharm takes the position that this is a simple debt collection matter. Hexo asked for  
and received CBD resin from MediPharm pursuant to the Supply Agreement but has  
refused to pay for it. This is precisely the type of case amenable to a motion for summary  
[87] In relation to the acquisition by Hexo of Newstrike, MediPharm, argues that it had no  
indication that the acquisition was going to take place prior to negotiating the Supply  
Agreement. The Supply Agreement was agreed upon prior to the public announcement  
on March 13, 2019. In fact, the first large shipment of cannabis resin had been made  
prior to that announcement.  
[88] MediPharm acknowledges that there were issues in respect of implementing the Supply  
Agreement. However, it acted in good faith to work with UP Cannabis, and later Hexo,  
in an attempt to work out those issues. Ultimately, each party made concessions with  
respect to some of the outstanding issues. Those issues were resolved to the satisfaction  
of UP Cannabis and/or Hexo, and the product was accepted and paid for such that those  
disputes are now moot.  
[89] MediPharm urges me to find that there are no genuine issues requiring a trial with respect  
to its claim for the amounts owing on its invoices from Hexo, and with respect to the  
counterclaim asserted against it by Hexo.  
[90] Hexo takes the position that MediPharm and Newstrike entered into the Supply  
Agreement in bad faith. In doing so, Hexo asserts:  
(a) that the prices contained therein are inflated;  
(b) that the timing of the Supply Agreement is suspicious given that it was formulated  
on the eve of the Arrangement Agreement;  
(c) that the Supply Agreement was for far more product than UP Cannabis needed;  
(d) that UP Cannabis, at the time that the Supply Agreement was entered into, was  
not even licensed to sell the product it received; and  
(e) the product shipped by MediPharm was defective.  
[91] Shortly after acquiring the product from MediPharm in March, UP Cannabis was trying  
to sell the resin that it had just purchased. Furthermore, at the time UP Cannabis had no  
extraction capabilities to process resin into oil, no licence for the laboratory for which it  
planned to eventually conduct processing and no ability to use the vast quantities within  
its usable shelf-life.  
[92] Hexo has adduced evidence that in August of 2018, the price for resin was in the range of  
$0.03 to $0.04 per mg.  
[93] Hexo takes the position that MediPharm failed to provide the requisite product as  
requested, failed in its obligation of good faith in contractual dealing by refusing to  
renegotiate the Supply Agreement to provide for distillate at no extra charge and refused  
to accept the return of the THC that it had shipped in the early months of the Supply  
[94] As to Mr. Hwang, Hexo argues that he was in breach of his fiduciary duty by entering  
into a contract that was so favourable to MediPharm and unfavourable to UP Cannabis.  
[95] Hexo thus argues that these issues require a trial to determine.  
Mr. Hwang:  
[96] Mr. Hwang argues that Hexo has failed to adduce any evidence, or even plead, that Mr.  
Hwang acted dishonestly, fraudulently, in a conflict of interest or self-dealt. At worst, he  
entered into a bad contract. Mr. Hwang takes the position that the Supply Agreement  
was entered into in good faith with MediPharm with a view to Newstrike’s long term  
strategic business plan and was, in all respects, a legitimate contract. He argues that his  
decisions in that regard are fully insulated by the business judgment rule.  
[97] Mr. Hwang further asserts that Hexo had an ample period of due diligence between the  
time that the Arrangement Agreement was executed and the closing date. All of the  
concerns now raised with the Supply Agreement were known or could have been known  
during the due diligence period.  
[98] Mr. Hwang also relies upon the Release contained in s. 9.12 of the Arrangement  
[99] Mr. Hwang accordingly argues that there is no genuine issue for trial in respect of the  
counterclaim against him and that the counterclaim should be dismissed.  
The Law:  
Summary Judgment Motions:  
[100] Pursuant to Rule 20.04(2) of the Rules of Civil Procedure, the court shall grant summary  
judgment if it is satisfied that there is no genuine issue requiring a trial with respect to a  
claim or defence. The rule includes fact-finding powers under Rules 20.04(2.1) and (2.2)  
to weigh evidence, evaluate credibility, and draw inferences, provided that their use is not  
against the interests of justice.  
[101] The seminal case with respect to motions for summary judgment is Hryniak v. Mauldin,  
[2014] 1 S.C.R. 87, authored by Karakatsanis J. Therein, the Supreme Court described  
that summary judgment motions offer a solution to the oft slow and expensive system of  
civil procedure that culminates in a trial. A trial is not necessary if a summary judgment  
motion can achieve a fair and just adjudication, allowing the judge to make the necessary  
findings of fact, apply the law to those facts and is a proportionate, more expeditious and  
less expensive means to achieve a just result than going to trial.  
[102] At paragraph 66, Karakatsanis J. described the applicable test on a motion for summary  
judgment. First, the judge should determine if there is a genuine issue requiring trial  
based only on the evidence before her, without using the new fact-finding powers. If  
there does appear to be a genuine issue requiring a trial, the motions judge should then  
determine whether a trial can be avoided by using the enhanced powers found in Rules  
20.04(2.1) and (2.2). The use of such powers will not be against the interests of justice if  
they will lead to a fair and just result and will serve the goals of timeliness, affordability  
and proportionality in light of the litigation as a whole.  
[103] A number of principles have emerged and are frequently referenced in summary  
judgment motions. A party may not rest on allegations in its pleadings on a motion for  
summary judgment but instead must “put its best foot forward” or “lead trump or risk  
losing”. Furthermore, the court is entitled to assume that the record on a motion for  
summary judgment contains all the evidence the parties would present at trial. It is not  
open to a party resisting summary judgment to rely on the prospect that additional  
evidence may be tendered at trial to justify the necessity of proceeding to trial (see:  
James v. Chedli, 2021 ONCA 593 at para. 31).  
[104] It must be kept in mind that despite Karakatsanis J’s. comments regarding summary  
judgment motions being used expansively to improve access to justice, there is no  
imperative for courts to use such motions in every case. The overarching goal remains to  
have a fair process that results in a just adjudication of disputes (see: Royal Bank of  
Canada v. 1643937 Ontario Inc., 2021 ONCA 98, at para. 25). As noted by Nordheimer  
J.A. in Mason v. Perras Mongenais, 2018 ONCA 978, at para. 44, “nothing in Hryniak  
detracts from the overriding principle that summary judgment is only appropriate where it  
leads to a ‘fair process and just adjudication’”.  
[105] Where there are deficiencies in the record before the court on a summary judgment  
motion, it may be inappropriate for the motions judge to resolve the issues in dispute  
(see: FFO Fiberglass v. Distribution Composites, 2019 ONSC 4291, at para. 17).  
The Duty of Good Faith Performance of Contracts:  
[106] The Supreme Court of Canada discussed whether there was a duty of good faith  
performance of contracts under Canadian common law in Bhasin v. Hrynew, 2014 SCC  
71. Cromwell J., for the court, described the organizing principle as simply being that  
parties must perform their contractual duties honestly and reasonably, and not  
capriciously or arbitrarily (at para. 63). This requires that a contracting party have  
appropriate regard to the legitimate contractual interests of the contracting partner.  
However, “appropriate regard” for the other party’s interests does not require acting to  
serve those interests in all cases. It merely requires that a party not seek to undermine  
those interests in bad faith (see: para. 65).  
[107] Cromwell J. expanded upon this at para. 73, as follows:  
[73] …I would hold that there is a general duty of honesty in contractual  
performance. This means simply that parties must not lie or otherwise knowingly  
mislead each other about matters directly linked to the performance of the  
contract. This does not impose a duty of loyalty or of disclosure or require a party  
to forego advantages flowing from the contract; it is a simple requirement not to  
lie or mislead the other party about one’s contractual performance. Recognizing a  
duty of honest performance flowing directly from the common law organizing  
principle of good faith is a modest, incremental step. The requirement to act  
honestly is one of the most widely recognized aspects of the organizing principle  
of good faith: see Swan and Adamski, at 8.135; O’Byrne, “Good Faith in  
Contractual Performance: Recent Developments”, at p. 78; Belobaba; Greenberg  
v. Meffert (1985), 50 O.R. (2d) 755 (C.A.), at p. 764; Gateway Realty, at para. 38,  
per Kelly J.; Shelanu Inc. v. Print Three Franchising Corp. (2003), 64 O.R. (3d)  
533 (C.A.), at para. 69. For example, the duty of honesty was a key component of  
the good faith requirements which have been recognized in relation to termination  
of employment contracts: Wallace, at para. 98; Honda Canada, at para. 58.  
[108] The Supreme Court subsequently relied upon Bhasin v. Hrynew in C.M. Callow Inc. v.  
Zollinger, 2020 SCC 45. In C.M. Callow, Kasirer J., for the majority of the court,  
reinforced that parties must not lie or otherwise knowingly mislead each other about  
matters directly linked to the performance of the contract.  
[109] In 2021, the Supreme Court again examined the duty of good faith in contractual  
performance in Wastech Services Ltd. v. Greater Vancouver Sewerage and Drainage  
District, 2021 SCC 7. In that case, the waste removal contract provided to the municipal  
district the absolute discretion to allocate waste to various disposal facilities. Its  
reallocation resulted in reduction of Wastech’s profit. Wastech claimed that the  
municipal district had breached its duty to exercise contractual discretion in good faith.  
[110] The majority of the Supreme Court held that the duty to exercise contractual discretion in  
good faith requires the parties to exercise their discretion in a manner consistent with the  
purposes for which it was granted in the contract, or in other words, reasonably and not  
arbitrarily or capriciously. The duty is breached only where the discretion is exercised  
unreasonably, in a manner unconnected to the purposes underlying the discretion. The  
measure of fairness is what is reasonable according to the parties’ own bargain.  
Director Liability:  
[111] Directors owe a fiduciary duty to the corporation for whom they act. That duty requires  
them to act in the best interests of the corporation (see: BCE v. 1976 Debentureholders,  
[2008] 3 S.C.R., at para. 37).  
[112] This fiduciary duty requires a director to represent the interests of the corporation with  
undivided loyalty and to avoid conflicts of interest. The director must not put his or her  
self interests ahead of the corporation’s interests. A director or officer must act honestly  
and in good faith with a view to the best interests of the corporation. A director must  
avoid abusing their position to gain personal benefit (see: Peoples Department Stores v.  
Wise, [2004] 3 S.C.R. 461, at p. 447).  
[113] The business judgment rule provides that the court will look to see that directors make  
reasonable decisions, but not perfect ones. Provided the decision taken is within a range  
of reasonableness, the court ought not to substitute its opinion for that of the board even  
though subsequent events may cast doubt on the board’s determination. As long as the  
directors have selected one of several reasonable alternatives, deference is accorded to  
the board’s decision (see: Kerr v. Danier Leather Inc., [2007] 3 S.C.R. 331, quoting with  
approval from Weiler J.A. in Maple Leaf Foods Inc. v. Schneider Corp. (1998), 42 O.R.  
(3d) 177 (Ont.C.A.)).  
[114] In Peoples Department Stores, supra, Major and Deschamps JJ., stated as follows on pp.  
…However, even with good corporate governance rules, directors’ decisions can  
still be open to criticism from outsiders. Canadian courts, like their counterparts  
in the United States, the United Kingdom, Australia and New Zealand, have  
tended to take an approach with respect to the enforcement of the duty of care that  
respects the fact that directors and officers often have business expertise that  
courts do not. Many decisions made in the course of business, although  
ultimately unsuccessful, are reasonable and defensible at the time they are made.  
Business decisions must sometimes be made, with high stakes and under  
considerable time pressure, in circumstances in which detailed information is not  
available. It might be tempting for some to see unsuccessful business decisions as  
unreasonable or imprudent in light of information that becomes available ex post  
facto. Because of this risk of hindsight bias, Canadian courts have developed a  
rule of deference to business decisions called the “business judgment rule”,  
adopting the American name for the rule.  
[115] The reasoning behind the business judgment rule was explained by Binnie J. in Kerr,  
supra, on p. 361:  
“The traditional justifications for the rule argue against its application here. It is  
said, truly enough, that judges are less expert than managers in making business  
decisions. Moreover, business decisions often involve choosing from amongst a  
range of alternatives. In order to maximize returns for shareholders, managers  
should be free to take reasonable risks without having to worry that their business  
choices will later be second-guessed by judges. …”  
[116] However, the business judgment rule is only available if the director satisfies the rule’s  
preconditions of honesty, prudence, good faith and a reasonable belief that his or her  
actions were in the best interests of the company. The business judgment rule is just a  
rebuttable presumption that directors or officers act on an informed basis, in good faith  
and in the best interests of the corporation: Unique Broadband Systems, Inc. (Re), 2014  
ONCA 538 () at paras. 71-72.  
[117] Set off can be legal, equitable or contractual.  
[118] In legal set-off, as set out in s. 111 of the Courts of Justice Act, R.S.O. 1990, c. C. 43,  
there are two requirements. First, both obligations must be debts that are liquidated in  
nature. Second, the debts must be mutual cross-obligations, meaning debts due from  
either party to the other.  
[119] Equitable set-off arises where there is such a relationship between the claims of the  
parties that it would be unconscionable or inequitable not to permit a set-off. The  
Supreme Court of Canada in Holt v. Telford, [1987] 2 S.C.R. 193 (SCC), set out the  
relevant principles of equitable set-off, as follows:  
the party claiming set-off must show some equitable ground for being protected  
from his adversary’s demands;  
that ground must go to the very root of the plaintiff’s claim;  
the counterclaim must be so clearly connected with the plaintiff’s demand that  
it would be manifestly unjust to allow the plaintiff to enforce payment without  
taking into consideration the counterclaim;  
the claim and counterclaim need not arise out of the same contract; and  
unliquidated claims are on the same footing as liquidated claims.  
[120] The primary rule in awarding damages for breach of contract is that a wronged plaintiff is  
entitled to be placed in as good a position as he would have been in if there had been  
proper performance by the defendant of its contractual obligations. This is subject to the  
qualification that the defendant cannot be called upon to pay for avoidable losses  
resulting in an increase in the quantum of damages payable to the plaintiff. The plaintiff  
must take reasonable steps to avoid the unreasonable accumulation of damages (see: Red  
Deer College v. Michaels, [1976] 2 SCR 324, at pp. 330-1).  
[121] The burden is on the defendant to establish that a plaintiff has failed to mitigate:  
Thompsons Limited v. 617987 Ontario Inc., 2012 ONCA 178 (), at para. 45.  
Application of the Law to the Evidence:  
Hexo vs. MediPharm:  
[122] Hexo is attempting on this motion to paint a picture of conspiracy in which Mr. Hwang  
and MediPharm, knowing that Hexo’s acquisition of Newstrike was imminent, negotiated  
a secret Supply Agreement that was vastly over-inflated to the advantage of MediPharm  
and to the detriment of Hexo. Indeed, during argument, counsel for Hexo described that  
MediPharm and UP Cannabis “began to hatch a plan” culminating in the Supply  
[123] However, what is missing is any evidence whatsoever that Mr. Hwang personally  
benefitted from the Supply Agreement, thereby placing his personal interests in conflict  
with those of UP Cannabis/Newstrike, to whom he owed a fiduciary duty. There is no  
evidence of collusion between Mr. Hwang and MediPharm. In fact, Hexo has not even  
made that allegation, other than perhaps by innuendo. Importantly, Mr. Hwang was not  
confronted with any such allegation when he was cross-examined. Hexo had Mr. Hwang  
“in the witness box” and did not pursue any line of questioning that elicited evidence of  
[124] Hexo’s arguments demonstrate, in my view, a fundamental misunderstanding of contract  
law in Canada and seek to take the doctrine of good faith further than Canadian courts  
have been prepared to go. This is obvious from the following statement from Hexo’s  
46. In essence, MediPharm utterly failed to behave appropriately in the  
negotiation and formation of the Supply Agreement, creating obligations for UP  
Cannabis and then Hexo that were completely out of step with the market in terms  
of cost, volume and utility. Its bad faith behaviour pervaded the negotiations,  
execution and contract formation and resulting performance under the Supply  
Agreement. …”  
[125] Quite simply, Hexo is asking this court to require MediPharm to ensure that the Supply  
Agreement was a good deal for UP Cannabis. But the duty of good faith in contractual  
dealings does not go that far. MediPharm was under no such obligation at law. Imposing  
so strict an obligation would unduly restrain free market enterprise. In Bhasin, it was  
recognized that the common law of contract generally places great weight on the freedom  
of contracting parties to pursue their individual self-interest. In commerce, a party may  
sometimes cause loss to anothereven intentionallyin the legitimate pursuit of  
economic self-interest (see: para. 70).  
[126] What the duty of good faith does impose is that a party not mislead or lie to the other. In  
this case, there is simply no evidence that MediPharm lied to or misled anyone at UP  
Cannabis in respect of the Supply Agreement.  
[127] Mr. Shehata, on behalf of MediPharm was asked during cross-examination whether  
anyone raised any concerns about why UP Cannabis needed so much resin. Respectfully,  
the doctrine of good faith that applies to contractual law in Canada does not require  
MediPharm to inquire why UP Cannabis needed so much resin. It was sufficient that UP  
Cannabis expressed an interest in acquiring that much resin from MediPharm resin and  
that MediPharm had the ability to supply that amount. There was no obligation on the  
part of MediPharm to advise UP Cannabis that the Supply Agreement would likely  
oversupply them with cannabis resin. Such a duty would impose an obligation on a  
contracting party to make inquiries into the inner working of their counterparts. I do not  
accept that such a duty exists at law.  
[128] Similarly, MediPharm did not need to concern itself with whether UP Cannabis had the  
requisite licensing to use the cannabis resin, or whether UP Cannabis had the ability to  
pay for so much resin. MediPharm was under no legal duty to ensure that the Supply  
Agreement was beneficial to UP Cannabis. To the contrary, MediPharm was entitled to  
assume that their counterparts were quite capable of looking out for their own interests.  
[129] In any event, Mr. Shehata’s answer on cross-examination was that with the legalization  
of Cannabis 2.0 products in the fourth quarter of 2019 many companies were attempting  
to stockpile cannabis resin and oil. This is entirely consistent with the strategic business  
plan laid out by Mr. Hwang in his affidavits. I note that on his cross-examination, Mr.  
Hwang indicated that he had no concerns with the amount of resin that UP Cannabis was  
acquiring under the Supply Agreement. If Mr. Hwang had no concerns, why should  
[130] More importantly, Hexo has adduced not even a hint of evidence of any deception on the  
part of MediPharm in the formation of the Supply Agreement that might trigger the duty  
of good faith.  
[131] On the evidence before the court, the Supply Agreement was fully disclosed to Hexo  
during the due diligence period. It was placed in the data room, it was listed in the  
Confidential Information Memo and it was discussed between personnel for Newstrike  
and Hexo prior to the closing date. If Hexo had issues with the Supply Agreement, the  
time to raise its concerns was prior to closing, not afterwards and certainly not in  
litigation as against MediPharm.  
[132] Hexo has provided sundry reasons why the Supply Agreement was a poor contract from  
UP Cannabis’ perspective. Even if I were to accept that to be true, it is not the role of the  
court to unburden parties from unfavourable contracts. There is an obligation to not  
deceive or mislead, and in those circumstances, the court can intervene. But determining  
whether a contract is favourable or unfavourable ought not to be the purview of the court.  
In other words, even if this were a bad contract for UP Cannabis, and therefore Hexo, it  
does not mean that MediPharm was in breach of any duty of good faith.  
[133] Establishing a fair price depends on several variables. The other contracts produced in  
this litigation, however, make it clear that the prices established within the Supply  
Agreement were within a reasonable range as negotiated between two arms length  
companies. UP Cannabis obtained a better price than MediPharm’s initial offer. I  
therefore reject the assertion that the prices under the Supply Agreement were “inflated”.  
There certainly is a dearth of evidence to show that the prices contained within the  
Supply Agreement are so unreasonable as to warrant the court concluding that there was  
some form of collusion or bad faith at the expense of UP Cannabis and/or ultimately  
Hexo. It is not within the purview of the court to fix prices agreed upon between two  
sophisticated parties. The market has that function.  
[134] There is no evidence, despite the allegations advanced by Hexo, that the Supply  
Agreement was not merely the product of an arm’s length negotiation, conducted by  
several representatives of both parties. Although Mr. Hwang signed off on the Supply  
Agreement for UP Cannabis, he was not the only individual ostensibly looking out for  
UP Cannabis’ best interests.  
[135] I conclude that there is no genuine issue requiring a trial that the Supply Agreement is  
void ab initio. It is not.  
[136] Hexo takes issue with MediPharm sending THC products without receiving any Purchase  
Orders from Hexo asking for THC products. First of all, Hexo was under a positive  
obligation pursuant to the Schedule B of the Supply Agreement to send monthly Purchase  
Orders. It was Hexo that failed to do so. Secondly, pursuant to the Supply Agreement,  
there was no obligation to send either THC or CBD. In the absence of a timely Purchase  
Order, I agree with MediPharm that it would be a matter of MediPharm’s discretion.  
[137] The duty of good faith in exercising one’s discretion in fulfilling contracts requires that a  
party not exercise that discretion capriciously or arbitrarily, or unreasonably. There is  
nothing in the evidence that would suggest that MediPharm did so. I agree that  
MediPharm would have been at risk of triggering penalty clauses had they not delivered  
any product. This is not a situation where Hexo sent a Purchase Order requesting CBD  
and was given THC. Hexo sent no Purchase Order on time. Furthermore, once Hexo  
made it known that they did not want the THC, MediPharm made the exchange,  
rendering this argument moot. I find that there is no basis to complain that MediPharm  
was acting in bad faith with respect to providing THC rather than CBD in the  
[138] Hexo further complains that MediPharm had agreed to provide distillates for free and  
failed to do so and that this is a breach of the duty of good faith dealing. There is a  
difference in the evidence as Mr. McMillan deposes that such a promise was made and  
Mr. Shehata refutes that it was made. As pointed out earlier in my reasons, even Mr.  
McMillan’s evidence is equivocal. The MediPharm president “expressed an interest” and  
indicated that they would “consider” it. In an email dated July 17, 2019 from Mr.  
Shehata to Hexo personnel, including Mr. McMillan, Mr. Shehata points out that Hexo is  
in arrears. He further states as follows:  
“We understand that you desire to change the deal such that the product delivered  
would be distillate instead of resin. We would be happy to accommodate your  
desire but note that this would require further processing on our end which would  
result in additional fees. Our President, Keith Strachan, discussed this with James  
MacMillan. Keith subsequently sent a proposal to James and is awaiting his  
response. When a deal is reached, I would be happy to work with your legal team  
to paper an amendment reflecting the new arrangement.  
In terms of the bulk resin shipped in May and June, we would be happy to further  
process the resin already delivered pursuant to the agreement into distillate for  
you for a nominal fee to accommodate your request as our valued partner. This  
could be done pursuant to a processing agreement whereby we you (sic) send us  
the resin and we process it into distillate. Again, I would be happy to work with  
your legal team to paper this processing arrangement following our receipt of  
payment for the above-noted overdue amounts.  
If you connect me with your legal team, I can commence working with them on  
your desired amendment to the existing supply agreement as well as on a  
processing agreement to accommodate your request regarding processing the  
resin into distillate.”  
[139] Furthermore, an email dated July 22, 2019 from Mr. Shehata to Mr. McMillan at Hexo  
states as follows:  
“To summarize three points from our discussion:  
1. PaymentHexo will be making payment for May and June shipments  
soon and you will confirm exact timing for the payment to me by end of  
day tomorrow.  
2. May and June productYou will be sending draft terms and conditions as  
well as distillate product specifications for your review so that we can  
paper the specifics for the further processing of the May and June into  
distillate to accommodate your request. You will let me know timing as to  
when we can expect to receive these draft items on Wednesday. I’ll then  
work to finalize these items with you and your legal team.  
3. July and go forwardYou will send a response to Keith’s proposal to me  
so that we can try to reach a meeting of the mind in terms of a go-forward  
arrangement. You will let me know timing of your response to Keith’s  
proposal on Wednesday. Once we finalize the arrangement, I will work  
with you and our legal team on an amendment to our existing agreement.  
If I misunderstood any of the above-noted items then please let me know.  
Otherwise, I look forward to hearing from you tomorrow and Wednesday and to  
working with you on items 2 and 3 above.”  
[140] It is Hexo that relies on this email chain to show that MediPharm was willing to produce  
distillate but did not do so. Respectfully, the email chain clearly shows that MediPharm  
was open to amending the agreement in that respect, so long as Hexo paid for that  
service. The parties were subsequently unable to reach a deal.  
[141] I have scoured the documents in evidence. Importantly, there is nothing in writing from  
Hexo in response to the suggestion that Hexo pay a fee for the distillate indicating that  
there had been a verbal agreement otherwise. This includes the letter from Hexo’s  
counsel dated September 10, 2019 asserting that MediPharm is in breach of the Supply  
Agreement. That would have been an opportune time to raise with MediPharm that it had  
agreed to provide distillate at no extra costs. In fact, on November 14, 2019, Simon  
Barton of Hexo emailed MediPharm and inquired:  
“If I wanted to purchase distillate vs winterized resin for the remainder of our  
contractwould you be able to provide a quote for this?” (emphasis added)  
[142] On November 18, 2019, Mr. Barton wrote:  
“In this instance I am looking at only our current contract obligations. I can  
consider taking distillate instead of resin but only for the remainder of the contract  
and for the established quantities. We could technically start this as soon as you  
could accommodate it, if the pricing makes sense.” (emphasis added)  
[143] Hexo’s own correspondence leads strongly to the inference that there was no oral  
agreement that MediPharm would provide distillate at no extra charge. Even if there was  
such evidence, the Supply Agreement could only be amended in writing.  
[144] Parties are clearly free to amend an existing contract. Thus, when Hexo approached  
MediPharm in the hopes that MediPharm would alter the agreement and provide distillate  
instead of resin, Hexo was well within its rights to make that request. However,  
MediPharm was not legally obligated, in my opinion, under the guise of a duty of good  
faith, to amend the Supply Agreement unless the terms of the proposed amendment were  
acceptable to MediPharm. In my view, MediPharm was entitled to hold Hexo to the  
Supply Agreement that had been negotiated at arm’s length with UP Cannabis.  
[145] Contrary to the assertions of Hexo, there were indicia of MediPharm attempting to work  
with Hexo in good faith. MediPharm did, in fact, exchange CBD product for THC  
product when asked to do so. When the pesticide and potency issues arose, MediPharm  
worked with UP Cannabis to ultimately resolve that issue to the satisfaction of UP  
Cannabis, including providing a credit of $150,000.  
[146] I conclude that there is no genuine issue requiring a trial with respect to whether  
MediPharm breached its duty of good faith in contractual performance. I find that it did  
[147] Finally, I agree with the position of MediPharm that Hexo cannot revisit shipments that  
were accepted and paid for. All of the THC that Hexo wants to return is from shipments  
made prior to June 2019. I accept that there were issues with potency, but ultimately UP  
Cannabis was satisfied with the arrangement the parties struck. Similarly, the pesticide  
issue was resolved in a manner that was clearly satisfactory to both parties. Hexo also  
inherited that decision from UP Cannabis.  
Hexo vs. Mr. Hwang:  
[148] It is fatal to Hexo’s claim as against Mr. Hwang that they have not provided a scintilla of  
evidence indicating that he was self-dealing or acting in conflict to the best interests of  
UP Cannabis/Newstrike. There is no evidence of deceit on Mr. Hwang’s part vis-à-vis  
either of UP Cannabis or Newstrike. I reiterate that Mr. Hwang was cross-examined  
extensively and no evidence on these issues emerged.  
[149] Hexo takes the position that it was not advised in advance of the May 24, 2019 closing  
date about issues arising under the Supply Agreement with MediPharm pertaining to  
pesticide testing, potency, efforts to amend the Supply Agreement and UP Cannabis’  
inability to sell resin. Respectfully, they have not advanced a cause of action as against  
Mr. Hwang that would bring any of those issues to the forefront. They have not sued Mr.  
Hwang for misrepresentation. Mr. Hwang, during that period of time, was not a fiduciary  
in respect of Hexo. Mr. Hwang was not contracting with Hexo so would not owe Hexo  
any duty of good faith. I agree that any duty of good faith that Mr. Hwang owed during  
the negotiation of the Supply Agreement would be to MediPharm.  
[150] It is clear that Hexo is dissatisfied with the Supply Agreement that UP Cannabis entered  
into with MediPharm. Hexo clearly believes that it was a bad deal from UP Cannabis’  
perspective. However, Hexo had a significant opportunity to undertake due diligence  
before the Arrangement Agreement closed. The Supply Agreement was available to  
them to review and inquire about.  
[151] On his cross-examination, Mr. McMillan confirmed the following about the due diligence  
Hexo knew that there was a difference between resin and distillate prior to  
acquiring Newstrike;  
After reviewing the Supply Agreement, Hexo knew that it was for the supply of  
Hexo knew and understood that UP Cannabis had limitations with their extraction  
Hexo had access to UP Cannabis’ licences in the data room and could review  
those licences;  
After reviewing the Supply Agreement, Hexo knew that the Supply Agreement  
did not provide UP Cannabis with the ability to alter or delay the delivery  
After reviewing the Supply Agreement, Hexo knew that it did not provide UP  
Cannabis with a provision for market pricing adjustments; and  
Hexo was aware of the quantities of resin being purchased under the Supply  
Agreement and knew that resin had a “shelf-life”.  
[152] In short, I find that Hexo had every opportunity during the due diligence period to  
investigate the Supply Agreement and determine whether or not it was so onerous that the  
terms of the acquisition should be altered, or the acquisition foregone. Despite this  
opportunity, Hexo chose to close the transaction. It does not now lie in its mouth to  
complain about the transaction.  
[153] I have considered the text messages uncovered by Hexo in this litigation from March of  
2019, as well as the internal emails from the same period. There is no question that  
concerns from UP Cannabis’ perspective with the Supply Agreement came to light  
quickly, in that the Supply Agreement did not assure UP Cannabis of receiving CBD.  
They were clearly looking to resell the resin and having no success. However, the texts  
and emails fall far short in suggesting any self-dealing on the part of Mr. Hwang. They  
simply reinforce that UP Cannabis entered into an unfavourable deal. The text messages  
do refute that MediPharm and Mr. Hwang were somehow in collusion.  
[154] Mr. McMillan indicated that there were concerns raised with Newstrike during the due  
diligence period and assurances were provided in response to those concerns. First of all,  
there is evidence that Newstrike’s team disclosed “speed bumps”. Secondly, the  
counterclaim does not advance misrepresentation as a cause of action. Thirdly, the entire  
agreement clause provided that no representations or warranties would survive past the  
date of closing and would be a barrier to that claim in any event.  
[155] Hexo does not have a remedy as against Mr. Hwang. In my view, the business judgment  
rule applies. There is not a trace of evidence presented that Mr. Hwang was self-dealing.  
He has laid out in his affidavits that Newstrike had a strategic business plan that required  
a large quantity of cannabis oil and that with Trevor Folk on board, UP Cannabis was  
positioned to begin extracting oil from the resin in the future. I also accept Mr. Hwang’s  
evidence that the necessary licence would be easily obtained.  
[156] It must be remembered the prevailing context in which the Supply Agreement was  
entered into. The cannabis industry was nascent and companies were scrambling to  
prepare themselves for the legalization of Cannabis 2.0 products. Decisions had to be  
made quickly and without a substantial historical basis for comparison. This is precisely  
the type of context where it is inappropriate for the court to second guess directors who  
are exercising their judgment, even if their judgment turns out to have been poor.  
[157] The Supply Agreement may have been a bad deal for UP Cannabis, in hindsight.  
However, the business judgment rule prevents the court from assuming the role of  
Monday morning quarterback in respect of a bona fide decision where the decision-maker  
believed that the transaction would be to the company’s benefit. There is no evidence  
before this court that Mr. Hwang is in breach of his fiduciary duty to Newstrike. Mr.  
Hwang was cross-examined on his affidavit and was not asked any questions about self-  
dealing. He should have been. There is simply no evidence that he placed his own  
interests in conflict with the corporate interests of Newstrike, or UP Cannabis.  
[158] Hexo was obligated to respond to this summary judgment motion by putting its best foot  
forward. A summary judgment motion judge is entitled to expect that all of the evidence  
that will be available at trial is presented on the motion. There has been ample time to  
develop evidence showing some form of self-interested behaviour on the part of Mr.  
Hwang. No such evidence has been presented.  
[159] 969625 Ontario Ltd. v. Goldstone Resources Inc., 2017 ONSC 879 (), which  
Hexo relies upon, is distinguishable on the facts. The contract that was the subject matter  
of that case was entered into between the plaintiff director and the corporation to which  
he owed a fiduciary duty. Thus, he acted in a conflict of interest when he negotiated a  
“lopsided” termination provision in his favour and the business judgment rule was not  
available to him. That was the same issue that confronted the Court of Appeal in Unique  
Broadband Systems, supra, relied upon heavily in Goldstone. Again, the board of  
directors breached their fiduciary duties when they awarded themselves certain benefits  
to the detriment of the corporation. In such cases, the business judgment rule does not  
[160] In the within case, I reiterate that there is zero evidence that Mr. Hwang derived any  
personal benefit from the Supply Agreement at the expense of UP Cannabis and/or  
Newstrike. Furthermore, I disagree with Hexo that the court does not have evidence as to  
Mr. Hwang’s decision-making process. To the contrary, he has taken great pains to  
explain the companies’ strategic business plan. It is particularly noteworthy that Mr.  
Folk was central to that strategic business plan and left the company.  
[161] While I think it sufficient that I rely upon the business judgment rule to exonerate Mr.  
Hwang in respect of the counterclaim, I will address the “No Liability” clause at s. 9.12  
of the Arrangement Agreement. For ease of reference, I reiterate that the clause provides:  
9.12 No Liability  
No director or officer of Purchaser shall have any personal liability whatsoever to  
Company or any third-party beneficiary under this Agreement and the Plan of  
Arrangement or any other document delivered in connection with the  
Contemplated Transactions on behalf of Purchaser. No director or officer of  
Company shall have any personal liability whatsoever to Purchaser under this  
Agreement and the Plan of Arrangement or any other document delivered in  
connection with the transactions contemplated hereby on behalf of Company.  
[162] I agree with Mr. Hwang that this clause bars any claim as against Mr. Hwang personally  
in respect of any representations or omissions that he may be alleged to have made about  
the Supply Agreement to Hexo. Those would properly fall “under this Agreement”.  
However, on a proper interpretation of s.9.12 of the Arrangement Agreement, I question  
whether it would protect Mr. Hwang from causes of action asserted against him if he was  
found to have breached his fiduciary duty vis-à-vis UP Cannabis/Newstrike. In my view,  
such a breach would not properly fall “under this Agreement”.  
[163] Thus, in my view, the “No Liability” clause prevents Hexo from suing Mr. Hwang, a  
director of Newstrike (“the Company”) for the alleged failure to provide particulars of the  
Supply Agreement to Hexo during the acquisition. It would not shield him in relation to  
a claim brought by Newstrike, and perhaps Hexo as successor, complaining that he  
engaged in self-dealing. In any event, I have already found that the evidence of self-  
dealing is non-existent. I also note that fraud, for example, is not pleaded. I also note  
that many of the misrepresentations raised in the evidence, although not pleaded, were  
not made by Mr. Hwang to Hexo in any event, but by other persons on behalf of  
Newstrike/UP Cannabis.  
[164] Hexo raises equitable set-off in its factum. However, it has provided no evidentiary basis  
by which MediPharm could owe Hexo any money pursuant to the Supply Agreement.  
Any basis for a claim of equitable set-off would arise from issues that were fully resolved  
by MediPharm and either UP Cannabis or Hexo during the course of their dealings.  
Quite simply, the requisite debt has not been established to be owing from MediPharm to  
Hexo for set-off to apply, either as a defence or as a counterclaim.  
[165] Furthermore, I do not conclude that fairness in this case somehow entitles Hexo to any  
right of set-off as against MediPharm.  
[166] I have considered the duty to mitigate.  
[167] In contract law, the non-breaching party is entitled to be placed in the same position that  
it would have been in had the contract been performed. MediPharm has not sought the  
full amount that Hexo would have paid to it had the Supply Agreement been honoured  
through to the end of its term in February of 2020. Instead, MediPharm has sought the  
actual amount that remains unpaid for the cannabis resin that was actually supplied to  
Hexo, plus the deposit that was to have been paid in January 2020. Importantly,  
MediPharm did not supply any product in January of 2020.  
[168] MediPharm has not included the balance of the amount that would have been paid in  
January 2020 after the cannabis resin was shipped. MediPharm has not included either  
the deposit owing at the beginning of February 2020 or the amount it would have  
received after shipping the February 2020 resin. In my view, MediPharm could have  
done so and I suspect might have had they not issued the Statement of Claim on January  
24, 2020, prior to those three later payments being considered overdue.  
[169] A party is required to take reasonable steps to mitigate its own losses, not the losses of  
the other party. Hexo is asking this court to find that MediPharm, after having had its  
product accepted and paid for, should have its damages reduced because it would not  
accept the product back and resell it. But doing so would mitigate Hexo’s loss, not  
MediPharm’s loss. What MediPharm was required to do was mitigate its own losses,  
presumably by re-selling the cannabis products that it would have sold to Hexo in  
January and February 2020 to another purchaser.  
[170] I was tempted to exercise the power provided under Rule 20.04 (2.2) and conduct a mini-  
trial with respect to whether MediPharm should have been able to re-sell the cannabis  
resin destined for Hexo to someone else. Had I been inclined to do so, I would have  
ordered that Hexo pay the outstanding amount to MediPharm less the January 2020  
deposit pending my decision on the mini-trial.  
[171] However, I have concluded that it is not in the interests of justice to do engage the power  
to hold a mini-trial. Mitigation should not have been an unanticipated issue on this  
motion for summary judgment. It is for Hexo to prove a failure on the part of  
MediPharm to mitigate. It was incumbent upon Hexo to adduce the evidence necessary  
for the court to adjudicate on this issue. This could have easily been accomplished during  
the cross-examination of Mr. Shehata but was not.  
[172] In large measure, MediPharm has recognized its duty to mitigate by not pursuing the  
remainder of the payments for the balance of the term of the Supply Agreement.  
[173] Having failed to adduce the necessary evidence to establish that MediPharm has failed to  
mitigate, Hexo has not met its onus and I am not prepared to reduce the quantum of  
damages owing on the basis of a failure to mitigate.  
Application of Hyrniak:  
[174] I will explain why I believe that it is appropriate to grant summary judgment in this case.  
[175] The first question I must ask myself is whether, only on the evidence before me, without  
using the enhanced fact-finding power, there is a genuine issue for trial. This is satisfied  
if the summary judgment process provides me with the evidence required to fairly and  
justly adjudicate the dispute and provides a timely, affordable and proportionate  
procedure to do so.  
[176] This is an appropriate case for summary judgment, in my opinion. There are no factual  
issues that need to be determined through a trial that have any bearing on the outcome of  
MediPharm’s claim against Hexo or Hexo’s counterclaim against Mr. Hwang. Those  
claims rest upon whether there is sufficient evidence of bad faith by MediPharm and/or  
Mr. Hwang, or a breach of fiduciary duty with respect to Mr. Hwang. The evidence that  
was adduced on the motion does not even provide a thread that could be pulled that leads  
me to believe that better evidence would emerge at trial on these issues.  
[177] There is a robust evidentiary record before me, including fulsome cross-examinations. I  
have sifted through and pored over an incredible amount of evidence. I am satisfied that  
the vast quantity of evidence provides an abundant record to resolve the case on its  
merits. To the extent that there is any deficiency in the evidence, it was the complete  
lack of any evidence of bad faith and self-dealing. But I do not find any deficiency. I  
find only that Hexo failed to provide any evidence of bad faith or self-dealing.  
[178] Furthermore, while Hexo argues that the court requires viva voce evidence from many  
key individuals involved in the negotiation and implementation of the Supply Agreement,  
I entirely disagree. That evidence cannot establish a breach of the duty of good faith  
because Hexo is, quite simply, asking for the duty of good faith to be stretched too far.  
[179] I agree with the submissions of MediPharm that I ought not to be dissuaded by the  
magnitude of the claim. In some cases it may be appropriate to consider the quantum of  
the amount in issue in the dispute when considering proportionality. But in this case, the  
principles are, I find, straight forward. MediPharm contracted with UP Cannabis, and  
ultimately Hexo to supply cannabis resin. Hexo eventually received the product for  
which it contracted for but refuses without legal justification to pay for it. The fact that  
the amount unpaid is approximately $10 million as opposed to $50,000 does not make  
summary judgment disproportionate in this case.  
[180] Further, given the extensive record before me, this is a case where the timely resolution  
of the case takes on importance. There is no question that our civil system is facing  
backlog and a scarcity of judicial resources and there would be more delay than usual in  
having this case reach a triala trial which in my view will add little in furtherance of  
resolving the dispute.  
[181] Hexo raises the spectre of calling 20 witnesses to provide context to the negotiations with  
respect to the Supply Agreement and what was imparted to Hexo during the period of due  
diligence. That exercise, in my view, would be disproportionately time consuming and  
excessively expensive, with little to no value added with respect to the issues that are  
determinative of this dispute.  
[182] As already mentioned, Hexo was required to put its best foot forward. It is not open to  
Hexo to state that further evidence will be available at trial. MediPharm’s motion was  
returnable 18 months in advance of the hearing date. Mr. Hwang’s motion was  
returnable 15 months in advance of the hearing date. Hexo had ample opportunity and  
did conduct thorough cross-examinations of Mr. Shehata and Mr. Hwang. If any of the  
20 witnesses were going to adduce evidence of self-dealing, for example, on the part of  
Mr. Hwang, the time to adduce at least some of that evidence was during this motion.  
[183] To summarize then, with respect to MediPharm’s claim against Hexo and Hexo’s  
counterclaim against Mr. Hwang, I conclude that I am able to reach a fair and just  
determination on the merits and that there is no genuine issue requiring a trial. I do so  
without engaging the enhanced fact-finding powers.  
[184] With respect to the counterclaim by Hexo against MediPharm for breach of the Supply  
Agreement, I do find that it is necessary to rely upon the enhanced fact-finding powers,  
namely weighing the evidence and drawing inferences. I have done so where appropriate  
in my discussion above.  
[185] Although there are some issues of credibility that perhaps should not be resolved on  
motion, credibility issues need not be resolved at all to determine this case. Even if  
resolved entirely in Hexo’s favour, the evidence would not engage the duty of good faith  
in this context, or a breach of fiduciary duty by Mr. Hwang. Quite simply, it is not a  
breach of any duty of good faith on MediPharm’s part not to renegotiate the Supply  
Agreement even if I accept Hexo’s evidence on that issue. There was still no amendment  
in writing as required. Mr. Hwang was not a fiduciary in respect of Hexo in the event  
that he failed to provide details about the pricing logic or how Hexo would be able to use  
the resin to Hexo. He is also shielded by the “No Liability” clause in that respect.  
[186] In my view, it is wholly appropriate for me to weigh the evidence and draw reasonable  
inferences and it is not in the interests of justice for these powers only to be exercised at  
trial. First of all, I have engaged these enhanced fact-finding powers sparingly. For the  
most part, I am able to conclude that there was no breach of the duty of good faith in  
contractual dealings by MediPharm without relying on those powers. However, I did  
draw inferences with respect to the lack of anything in writing from Hexo suggesting that  
MediPharm had agreed to provide distillate at no extra charge.  
[187] It is my view that my limited reliance upon the enhanced fact-finding powers enabled me  
to fairly and justly adjudicate the claim and spared all parties unnecessary time and  
expenses. On the record before me, I am able to make the necessary findings of fact and  
apply the law to those facts.  
[188] I am prepared to accept that the Supply Agreement has been a bad contract from Hexo’s  
perspective. It may have turned out to be a good contract had UP Cannabis maintained  
its course with Trevor Folk in the mix, as Mr. Hwang believed. It is not the role of the  
court to relieve Hexo from a bad contract, absent some evidence of patent unfairness in  
the manner in which the contract was negotiated or performed. That evidence does not  
exist in this case.  
[189] Ultimately, there is no evidence to suggest that Mr. Hwang did not legitimately believe  
that the Supply Agreement would assist UP Cannabis and Newstrike in furthering their  
corporate goals. The Supply Agreement was negotiated between arm’s length parties.  
There is absolutely no evidence adduced that Mr. Hwang derived any personal benefit  
from this transaction that the court could find untoward.  
[190] Additionally, Hexo had ample opportunity to examine the merits of the Supply  
Agreement during its two months long due diligence period. It had the ability to evaluate  
the strengths and weaknesses of the Supply Agreement and it proceeded to complete the  
acquisition of Newstrike.  
[191] MediPharm supplied cannabis resin in accordance with the Supply Agreement. There  
were wrinkles and those wrinkles were ironed out to the satisfaction of UP Cannabis and  
then later Hexo, at least enough that they continued to order more resin. When satisfied,  
UP Cannabis and/or Hexo accepted the shipments and made payments to MediPharm,  
until Hexo stopped paying, without legal justification.  
[192] There is no evidence that MediPharm acted in bad faith during the performance of its  
contractual obligations. To the contrary, MediPharm took active steps to credit UP  
Cannabis and exchange product already shipped. They also indicated a willingness,  
despite no obligation to do so, to renegotiate the Supply Agreement but the parties were  
unable to come to an agreement.  
[193] To be blunt, I find that the positions taken by Hexo in its defence of the claim, and with  
respect to its counterclaims, to be legally untenable on the evidence.  
[194] Accordingly, I grant summary judgment in favour of MediPharm for the sum of  
$9,802,032.78 plus interest. If there is any issue with respect to the calculation of  
interest, the parties may contact me through the London trial coordinator. MediPharm is  
also entitled to the costs of the action and this motion.  
[195] I grant summary judgment in favour of MediPharm in respect of the counterclaim and  
dismiss the counterclaim as against MediPharm with costs.  
[196] I grant the summary judgment motion in favour of Mr. Hwang in respect of the  
counterclaim and dismiss the counterclaim as against Mr. Hwang with costs.  
[197] If the parties are unable to agree on the costs of the action, including the counterclaim,  
and the motions, MediPharm and Mr. Hwang may each provide written submissions no  
longer than 4 pages in length no later than September 2, 2022 through the London trial  
coordinator. These should be accompanied by any applicable offers and a Bill of Costs.  
[198] Responding costs submissions, also no longer than 4 pages in length, to be submitted no  
later than September 16, 2022. There shall be no reply submissions unless subsequently  
asked for by me.  
[199] Motions for summary judgment granted.  
“Justice S. Nicholson”  
Justice Spencer Nicholson  
Date: July 25, 2022  

© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission